Serum Cytokines in Metastatic Melanoma Patients Treated with an Autologous Tumor Vaccine

Publisher Website
Google Scholar
Abstract
Short-term autologous tumor vaccines were established and used to treat metastatic melanoma patients. Serum samples obtained prior to (week 0) and after three vaccinations (week 4) were assayed for interleukin (IL)-2, interferon (IFN)-γ, IL-4, and IL-10. Results (mean ± SD) for 30 patients who had matching serum samples obtained at weeks 0 and 4 were: week 0, IL-2, 122 ± 320 pg/mL; IFN-γ, 0.1 ± 0.4 IU/mL; IL-4, 10.0 ± 19 pg/mL; IL-10, 159 ± 237 pg/mL; week 4: 119 ± 308 for IL-2; 0.1 ± 0.4 for IFN-γ; 16 ± 29 for IL-4, and 210 ± 273 for IL-10. Medium conditioned by tumor cell lines demonstrated relatively low levels of secreted IL-10 (3.5 ± 4.2 pg/106 cells/mL/96 hours), which would not account for the observed serum levels. In conclusion, the serum cytokine pattern from these patients suggests that the immune system is being modulated prior to and subsequent to vaccination.